What it's for (Indications)
- Flavoxate + Propyphenazone combination is primarily indicated for the symptomatic relief of pain and spasms associated with various conditions of the lower urinary tract.
- This includes, but is not limited to, dysuria (painful urination), urgency, nocturia (frequent urination at night), suprapubic pain, and frequency, which may arise from cystitis, urethritis, prostatism, or other irritative states of the bladder and urethra.
- It is also used post-operatively following urological procedures or instrumentation, where pain and bladder spasms are common.
- The flavoxate component acts to relax the smooth muscles of the urinary tract, alleviating spasms, while propyphenazone provides potent analgesic and antipyretic effects, addressing pain and inflammation and contributing to overall symptomatic relief in these conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical adult dosage for flavoxate + propyphenazone combination, exemplified by brands like Cystalgon, generally involves oral administration of one to two tablets, two to three times daily, depending on the severity of symptoms and the specific formulation's strength. Dosing should be individualized based on the patient's response and tolerance, always adhering strictly to the manufacturer's recommended guidelines and a healthcare professional's prescription. It is crucial to administer the medication with food or milk to minimize potential gastrointestinal irritation, particularly due to the propyphenazone component. The duration of treatment should be as short as possible to manage acute symptoms effectively, and it is imperative not to exceed the prescribed dose or duration. Pediatric dosing information, if available, would be specific to the formulation and clinical context, and should always be determined by a qualified healthcare professional. |
Safety & Warnings
Common Side Effects
- The combination of flavoxate and propyphenazone can elicit a range of side effects, stemming from both active components.
- Common adverse effects attributed to flavoxate include gastrointestinal disturbances such as nausea, vomiting, dyspepsia, and dry mouth.
- Central nervous system effects like dizziness, headache, drowsiness, blurred vision, and nervousness may also occur.
- Propyphenazone, being an NSAID, commonly causes gastrointestinal side effects including abdominal pain, indigestion, nausea, and diarrhea.
- More serious, albeit rare, side effects of propyphenazone include gastrointestinal ulceration or bleeding, renal impairment, hepatic dysfunction, hypersensitivity reactions (e.
- g.
- , skin rashes, itching, urticaria), and hematological abnormalities such as leukopenia, thrombocytopenia, and, most critically, agranulocytosis, which requires immediate medical attention.
- Patients should be advised to report any unusual or severe symptoms to their healthcare provider immediately for proper evaluation.
Serious Warnings
- Black Box Warning: While a formal FDA Black Box Warning specific to the combined product flavoxate + propyphenazone does not universally exist, the critical safety concerns associated with its components, particularly propyphenazone, necessitate a prominent 'Serious Warnings' section highlighting these substantial risks. **SERIOUS WARNINGS:** Propyphenazone, a pyrazolone derivative, carries a significant risk of severe hematological reactions, most notably agranulocytosis, which can be life-threatening. Although rare, this adverse effect can occur suddenly and without warning, potentially leading to fatal infections. Regular monitoring of blood counts is advisable during prolonged treatment, and patients should be immediately counselled to report any signs of infection (e.g., fever, sore throat, mouth ulcers), unexplained bleeding, or bruising. Prompt discontinuation of the drug and medical evaluation are crucial if such symptoms arise. Furthermore, like other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), propyphenazone can increase the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with pre-existing cardiovascular disease or risk factors. NSAIDs also increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can also be fatal. These events can occur at any time during use and without warning symptoms, particularly in older patients. The use of this medication should be avoided or used with extreme caution in patients with significant risk factors for these serious adverse events, and the lowest effective dose for the shortest possible duration should be utilized to mitigate these risks.
- This medication requires careful consideration due to the pharmacodynamic profiles of its components.
- Patients with a history of gastrointestinal ulceration or bleeding, or those predisposed to such conditions, should use this drug with extreme caution due to the propyphenazone content, which carries a risk of serious GI adverse events, including perforation.
- Renal and hepatic function should be monitored, especially in patients with pre-existing impairment, as both components are metabolized and excreted by these organs.
- Cardiovascular risks, including an increased risk of thrombotic events, myocardial infarction, and stroke, are associated with NSAIDs like propyphenazone, particularly with prolonged use or in patients with pre-existing cardiovascular disease.
- Flavoxate's anticholinergic properties necessitate caution in patients with glaucoma, urinary retention, or benign prostatic hypertrophy, as it can exacerbate these conditions.
- Hypersensitivity reactions, ranging from skin rashes to severe anaphylactic shock, can occur, and treatment should be discontinued immediately if such reactions manifest.
- Careful patient selection and monitoring are paramount.
How it Works (Mechanism of Action)
Flavoxate + Propyphenazone exerts its therapeutic effects through a dual mechanism addressing both spasm and pain in the urinary tract. Flavoxate hydrochloride functions as a direct-acting spasmolytic agent, primarily on the smooth muscle of the urinary tract. Its mechanism involves a direct relaxant effect on the detrusor muscle, helping to alleviate the spasms and involuntary contractions responsible for symptoms like urgency, frequency, and nocturia. Additionally, flavoxate exhibits weak anticholinergic (antimuscarinic) properties, further contributing to its antispasmodic action by blocking acetylcholine receptors, which can help in reducing bladder overactivity. Propyphenazone, a non-steroidal anti-inflammatory drug (NSAID) and a pyrazolone derivative, acts primarily by inhibiting the enzyme cyclooxygenase (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins. Prostaglandins are key mediators of pain, inflammation, and fever, so by inhibiting their production, propyphenazone provides potent analgesic (pain-relieving) and antipyretic (fever-reducing) effects, complementing flavoxate's spasmolytic action in relieving symptomatic discomfort in inflammatory conditions of the urinary tract.
Commercial Brands (Alternatives)
No other brands found for this formula.